Zydus Cadila gets final nod from USFDA to market generic seizures drug

Zydus Cadila has received final approval from the United States Food
and Drug Administration (USFDA) to market Lamotrigine extended-release
tablets USP in the strengths of 25 mg, 50 mg, 100 mg, 200 mg, 250 mg,
and 300 mg, Zydus Cadila said in a statement.

https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/zydus-cadila-gets-final-nod-from-usfda-to-market-generic-seizures-drug/articleshow/74948512.cms